Investigational drug · Phase 2
FHND1002
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Amyotrophic Lateral Sclerosis (ALS).
Phase 2Last checked: Nov 19, 2026Latest source record: Aug 22, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "FHND1002"
First trial start
2025
Oct 1, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "FHND1002", any sponsor or status.
Conditions studied
As listed on its trial records.
- Amyotrophic Lateral Sclerosis (ALS)
Approved drugs for the same conditions: ALS (amyotrophic lateral sclerosis) · Neurology
Largest trials
Live from ClinicalTrials.gov: studies naming "FHND1002" as an intervention, largest first.
- FHND1002 for ALS Treatment: Phase 2Pivotal-lookingNot yet recruiting
Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd.Industry
NCT07138014 · 180 participants (planned) · Start Oct 1, 2025 · Primary completion Dec 31, 2027
Drug: FHND1002 100mg; FHND1002 200mg and 1 more · For: Amyotrophic Lateral Sclerosis (ALS)
- Safety, Tolerability, and Pharmacokinetics of FHND1002 Granules in Healthy AdultsEnrolling by invitation
Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd.Industry
NCT06782958 · 72 participants (planned) · Start Jul 5, 2024 · Primary completion Mar 3, 2025
Drug: 50mg FHND1002; 100mg FHND1002 and 4 more · For: Amyotrophic Lateral Sclerosis (ALS)
Sites: Lanzhou, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Amyotrophic Lateral Sclerosis (ALS)
- MasitinibAB1010Phase 33 trials
AB Science · Amyotrophic Lateral Sclerosis, Amyotrophic Lateral Sclerosis (ALS), Alzheimer Disease
- COYA 302Phase 31 trial
Coya Therapeutics · Amyotrophic Lateral Sclerosis (ALS)
- ALT001Phase 22 trials
Darwin Origin (Hubei) Biopharmaceutical Co., Ltd. · Ischemic Stroke in the Sequelae Stage, Amyotrophic Lateral Sclerosis (ALS)
- VHB937Phase 22 trials
Novartis · Amyotrophic Lateral Sclerosis (ALS), Alzheimer's Disease
- NB-4746Phase 21 trial
Nura Bio · Amyotrophic Lateral Sclerosis (ALS)
- SNUG01Phase 21 trial
SineuGene Therapeutics Co., Ltd. · Amyotrophic Lateral Sclerosis (ALS)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.